Completed PHASE2 INTERVENTIONAL 4-arm NCT01648322

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Sponsor: EVIVE Biotechnology

Conditions Breast Cancer Neutropenia

Interventions F-627 Neulasta® (pegfilgrastim)

Updated 11 times since 2017 Last updated: Oct 2, 2018 Started: Jun 30, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01648322, this PHASE2 trial focuses on Breast Cancer and Neutropenia and remains completed. Sponsored by EVIVE Biotechnology, it has been updated 11 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Mar 2022 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Jan 2021 — Mar 2022 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Apr 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Apr 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EVIVE Biotechnology

Data source: EVIVE Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Anderson, United States